ANI Pharmaceuticals announced that the Phase 4 NEW DAY clinical trial results for its intravitreal implant ILUVIEN (fluocinolone acetonide) have been published in the peer‑reviewed journal Ophthalmology on April 7, 2026. The publication marks a key milestone in the company’s effort to expand the use of ILUVIEN for diabetic macular edema (DME) in patients who have previously been treated with corticosteroids and have not experienced a significant rise in intraocular pressure.
The NEW DAY study enrolled patients with DME who had prior corticosteroid exposure and no significant intraocular pressure (IOP) elevation. The primary endpoint—mean total number of supplemental aflibercept injections over 18 months—did not reach statistical significance (2.4 vs. 2.5; p = 0.756). However, the trial did demonstrate a statistically significant improvement in the time to first supplemental aflibercept injection in the ILUVIEN arm. Safety data were consistent with earlier reports: IOP ≥10 mm Hg from baseline occurred in 34% of ILUVIEN patients versus 10% of sham controls, and IOP ≥30 mm Hg occurred in 20% versus 4%. Cataract development was higher in the ILUVIEN group (82% vs. 50%), with 80% of ILUVIEN subjects undergoing cataract surgery compared with 27% of sham patients.
The publication comes at a time when ANI’s Rare Disease portfolio is delivering strong financial results. In Q4 2025, the company reported net revenues of $247.1 million, up 29.6% year‑over‑year, and a GAAP net income of $27.5 million, a turnaround from a $10.7 million loss the previous year. ILUVIEN and its companion product YUTIQ generated $19.8 million in Q4 2025 and $74.9 million for the full year, while the Rare Disease segment as a whole grew 50.8% to $131.3 million in Q4 2025. These figures underscore the commercial momentum behind ILUVIEN and its contribution to ANI’s high‑margin specialty product strategy.
CEO Nikhil Lalwani said, “We are proud that the results from the NEW DAY clinical trial have been published in Ophthalmology, a leading, globally respected peer‑reviewed journal. This publication represents our team’s continued commitment to generating clinical data for patients living with DME and for the overall retina community.” The statement highlights the company’s focus on evidence‑based expansion of its retinal indications.
The peer‑reviewed data reinforce ILUVIEN’s positioning as a long‑acting, steroid‑based therapy for chronic retinal disease and support ANI’s broader strategy of leveraging its U.S. manufacturing moat to deliver high‑margin specialty products. With the Rare Disease segment driving record growth, the new publication strengthens investor confidence in ANI’s commercialization pipeline and signals continued progress toward its goal of sustaining long‑term growth in a highly competitive specialty‑pharma market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.